title: [Long-term destiny of adolescents and young adults with de novo acute lymphoblastic leukemia treated with a pediatric protocol type].
abstract: BACKGROUND
  The prognosis, in the long term, of adolescents and young adults with acute de novo lymphoblastic leukemia, treated with a pediatric type protocol.
  
  
  OBJECTIVE
  To analyze the efficacy and tolerability of a chemotherapy regimen of pediatric type on patients 15-35 years old with de novo acute lymphoblastic leukemia, Ph(-).
  
  
  METHODS
  A retrospective study of patients received from 2001 to 2013, without initial infiltration of the central nervous system. They received the regimen called LALÍN. Terminal goals: frequency of initial remission, probability of survival free of leukemia and event-free survival for five years.
  
  
  RESULTS
  We included 101 patients; there were 29 relapses and 19 deaths. There was initial remission in 97% of the cases; survival free of leukemia of 0.58 and event-free survival 0.44. No difference in patients aged 16-21 years vs. 22-35 (p > 0.55). Negative prognostic factors: abnormal karyotypes, except hyperdiploids (p = 0.001); > 5% of blasts, on 14 day induction (p = 0. 0001); delay in the punctuality of the courses of the chemotherapy regimen (p = 0.0001).
  
  
  CONCLUSIONS
  A pediatric type regimen is applicable to patients aged from 16 to 35 years with acute lymphoblastic leukemia, without greater toxicity and a best survival free of leukemia. The count of > 5% of blasts and the delay in the execution of the stages of the chemotherapy regimen are the stronger negative prognostic factors.
authors: Servicio de Hematología, Centro Médico Nacional 20 de Noviembre, ISSSTE, Ciudad de México, México.
authors: Manuel Antonio
authors: MA
authors: López-Hernández
authors: Servicio de Hematología, Centro Médico Nacional 20 de Noviembre, ISSSTE, Ciudad de México, México.
authors: Martha
authors: M
authors: Alvarado-Ibarra
authors: Servicio de Hematología, Centro Médico Nacional 20 de Noviembre, ISSSTE, Ciudad de México, México.
authors: José Luis
authors: JL
authors: Álvarez-Veral
authors: Servicio de Hematología, Centro Médico Nacional 20 de Noviembre, ISSSTE, Ciudad de México, México.
authors: Maricela
authors: M
authors: Ortiz-Zepeda
authors: Servicio de Hematología, Centro Médico Nacional 20 de Noviembre, ISSSTE, Ciudad de México, México.
authors: Martha Lilia
authors: ML
authors: Guajardo-Leal
authors: Servicio de Hematología, Centro Médico Nacional 20 de Noviembre, ISSSTE, Ciudad de México, México.
authors: Xochitl
authors: X
authors: Cota-Range
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D060830:Consolidation Chemotherapy / Q000379:methods; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods; D060046:Maintenance Chemotherapy / Q000379:methods; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D003561:Cytarabine; D014750:Vincristine; D003907:Dexamethasone; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin